GLP1R and intestinal obstruction: While permanent discontinuation may be appropriate in some cases, other strategies, such as dose reduction or switching to an alternative GLP-1 RA with a different pharmacokinetic profile, may help preserve the metabolic benefits of therapy while mitigating the risk of bowel obstruction.